At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Wolfgang Hiddemann, MD, PhD, from the University of Munich, Munich, Germany, provides an overview of chemotherapy-free approaches in clinical development for the treatment of patients with indolent lymphoma. Promising approaches include the Bruton tyrosine kinase inhibitor, ibrutinib, and PI3K-delta inhibitor, idelalisib, in combinations with anti-CD20 monoclonal antibodies; Bcl-2 inhibitors; and PD-1 immune checkpoint inhibitors.